Cochrane · systematic review · CD008532
Combination inhaled steroid and long‐acting beta₂‐agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease
Rojas‐Reyes, MX, García Morales, OM, Dennis, RJ, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 4 · 57.1%Moderate 3 · 42.9%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyTiotropium + LABA/ICS combination compared with tiotropium for chronic obstructive pulmonary disease
Population: patients with chronic obstructive pulmonary disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality (all‐cause) Tiotropium + LABA/ICS combination vs tiotropium | OR 1.8 [0.55, 5.91] | 2 studies · 961 participants | Moderate Downgraded: imprecision |
Hospital admission (all causes) Tiotropium + LABA/ICS combination vs tiotropium | OR 0.84 [0.53, 1.33] | 2 studies · 961 participants | Low Downgraded: imprecision |
Exacerbation ‐ at 12‐month Tiotropium + LABA/ICS combination vs tiotropium | OR 0.89 [0.56, 1.41] | 1 study · 301 participants | Low Downgraded: imprecision |
Serious adverse events (non‐fatal) Tiotropium + LABA/ICS combination vs tiotropium | OR 0.86 [0.57, 1.3] | 4 studies · 1758 participants | Low Downgraded: risk of bias, imprecision |
Quality of life up to 6 months (SGRQ) Tiotropium + LABA/ICS combination vs tiotropium | no estimate extracted | 4 studies · 4 participants | Low Downgraded: risk of bias, imprecision |
FEV1 pre‐dose ‐ FEV1 3‐6 months mean difference Tiotropium + LABA/ICS combination vs tiotropium | no estimate extracted | 4 studies · 4 participants | Moderate Downgraded: risk of bias, imprecision |
FEV1 pre‐dose ‐ FEV1 1 year Tiotropium + LABA/ICS combination vs tiotropium | no estimate extracted | 1 study · 1 participants | Moderate Downgraded: imprecision |
Tiotropium plus LABA/ICS combination compared to Tiotropium plus placebo for chronic obstructive pulmonary disease
Population: patients with chronic obstructive pulmonary disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality (all cause) Tiotropium plus LABA/ICS combination vs Tiotropium plus placebo | OR 1.88 [0.57, 6.23] | 2 studies · 1021 participants | Low Downgraded: imprecision |
Hospital admission (all causes) Tiotropium plus LABA/ICS combination vs Tiotropium plus placebo | OR 0.84 [0.53, 1.33] | 2 studies · 961 participants | Low Downgraded: imprecision |
Hospital admission (exacerbation) Tiotropium plus LABA/ICS combination vs Tiotropium plus placebo | OR 0.66 [0.39, 1.13] | 2 studies · 961 participants | Low Downgraded: imprecision |
Exacerbation Tiotropium plus LABA/ICS combination vs Tiotropium plus placebo | no estimate extracted | 2 studies · 961 participants | Ungraded |
Pneumonia Tiotropium plus LABA/ICS combination vs Tiotropium plus placebo | OR 1.35 [0.31, 5.99] | 2 studies · 961 participants | Low Downgraded: imprecision |
Quality of life SGRQ scale ‐ Quality of life 3‐5 months mean difference + 1 yr SE Tiotropium plus LABA/ICS combination vs Tiotropium plus placebo | no estimate extracted | 2 studies · 961 participants | Low Downgraded: imprecision |